Education
About Us
Working with TipRanks
Follow Us
9 Meters Biopharma (NMTRQ)
OTHER OTC:NMTRQ
NMTRQ Stock Chart & Stats
<$0.01
$0.00(0.00%)
At close: 4:00 PM EST
<$0.01
$0.00(0.00%)
Day’s Range― - ―
52-Week Range<$0.01 - $3.14
Previous CloseN/A
Volume2.41K
Average Volume (3M)N/A
Market Cap
$1.45K
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta-36.76
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding14,459,690
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
9 Meters Biopharma News
NMTRQ FAQ
What was 9 Meters Biopharma’s price range in the past 12 months?
9 Meters Biopharma lowest stock price was <$0.01 and its highest was $3.14 in the past 12 months.
What is 9 Meters Biopharma’s market cap?
9 Meters Biopharma’s market cap is $1.45K.
When is 9 Meters Biopharma’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were 9 Meters Biopharma’s earnings last quarter?
Currently, no data Available
Is 9 Meters Biopharma overvalued?
According to Wall Street analysts 9 Meters Biopharma’s price is currently Overvalued.
Does 9 Meters Biopharma pay dividends?
9 Meters Biopharma does not currently pay dividends.
What is 9 Meters Biopharma’s EPS estimate?
9 Meters Biopharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does 9 Meters Biopharma have?
9 Meters Biopharma has 14,459,690 shares outstanding.
What happened to 9 Meters Biopharma’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of 9 Meters Biopharma?
Currently, no hedge funds are holding shares in NMTRQ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
9 Meters Biopharma
9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders in North America. Its lead product candidate is Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 3 clinical trial to treat short bowel syndrome. The company is developing NM-136, a humanized monoclonal antibody for the treatment of obesity and obesity-related disorders; NM-102, a small molecule peptide to prevent antigens from trafficking into systemic circulation; and NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease. Its partnered product is Larazotide, an 8-amino acid peptide, which is in Phase 2 clinical trial for treatment of multi-system inflammatory syndrome. The company has licensing agreements with Amunix, MHS Care Innovation LLC, Alba Therapeutics Corporation, and EBRIS. 9 Meters Biopharma, Inc. is headquartered in Raleigh, North Carolina. On July 17, 2023, 9 Meters Biopharma, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the Eastern District of North Carolina.
Salarius Pharmaceuticals
―
Scinai Immunotherapeutics
―
PainReform
―
Dermata Therapeutics
―
Virax Biolabs Group Ltd. Class A
―
Ownership Overview
―
Insiders
<0.01% Mutual Funds
11.67% Other Institutional Investors
88.32% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---